Hepatocellular Carcinoma (HCC)NCT07183566
CT Volume Measurement of Hepatocellular Carcinoma
An observational study of Hepatocellular Carcinoma (HCC) and CT, run by Assiut University.
Trial summary
The aim of this study is to evaluate the role of CT volumetric measurement in assessing treatment response of hepatocellular carcinoma (HCC) following trans arterial chemoembolization (TACE) or microwave ablation (MWA) Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hepatocellular Carcinoma (HCC), CT
- What is being tested?
- Ct
- Type of treatment
- Medical device
- How many people
- 66 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2025to 1 Nov 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: All patients admitted to Assiut University Hospital, Egypt during the period of the study and fulfil the inclusion criteria
Who may be able to join
- Adult patients (≥18 years) with a confirmed diagnosis of HCC based on AASLD or EASL criteria.
- Patients deemed unresectable by the multidisciplinary tumor board.
- Patients scheduled for TACE as the primary locoregional therapy.
- Preserved liver function (Child-Pugh class A or B).
- Adequate renal function to permit contrast-enhanced CT.
Who cannot join
- Patients with extrahepatic metastases or portal vein thrombosis.
- Patients with contraindications to iodinated contrast or TACE.
- Patients with severe comorbid illness that precludes participation.
- Patients refuse to provide informed consent.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Ct Volume Measurement of Hepatocellular Carcinoma After Transarterial Chemoembolization (TACE) or Microwave Ablation (MWA)
The aim of this study is to evaluate the role of CT volumetric measurement in assessing treatment response of hepatocellular carcinoma (HCC) following trans arterial chemoembolization (TACE) or microwave ablation (MWA)
Read the detailed description
Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer and a major contributor to cancer-related mortality worldwide (1). Conventional curative interventions for HCC encompass liver transplantation, hepatic resection, and thermal ablation. Regrettably, fewer than 30% of patients qualify for surgery upon diagnosis, and many tumor-related characteristics, including size and location, may inhibit the application of thermal ablative methods .
In these cases, locoregional therapies such as transarterial chemoembolization (TACE) and microwave ablation (MWA) play a pivotal role. Both techniques aim to achieve local tumor control and improve patient survival. TACE induces ischemic necrosis through targeted delivery of chemotherapeutic agents combined with arterial embolization, whereas MWA achieves tumor destruction by generating high-frequency electromagnetic waves that produce thermal coagulative necrosis. Accurate assessment of treatment response is essential for guiding clinical decisions and predicting outcomes. Conventional imaging-based response criteria, such as RECIST and mRECIST, primarily focus on changes in lesion diameter. However, these methods may not fully reflect the extent of tumor necrosis or viable residual tissue . In this context, CT-based volumetric measurements have emerged as a more objective and sensitive tool for evaluating therapeutic response after locoregional treatment. Volumetric analysis provides a three-dimensional assessment of tumor burden and may bet ter correlate with treatment efficacy and prognosis compared to traditional linear measurements. Therefore, this study aims to investigate the role of CT volumetric measurement of HCC after TACE or microwave ablation in evaluating treatment response and predicting clinical outcomes .
- Conditions
- Hepatocellular Carcinoma (HCC), CT
- Being tested
- Ct
- Medical subject headings
- Carcinoma, Hepatocellular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CtDevice
Ct volume measurement of HCC after TACE or MWA
What is being measured
The primary outcome is the main question the study is designed to answer.
Ct volume measurent of hepatocellular carcinoma after Transarterial chemoembolization or microwave ablation
At enrollment, all patients will undergo a comprehensive clinical assessment, including full medical history with emphasis on risk factors for hepatocellular carcinoma triphasic CT scan of the liver, which will serve as the reference for tumor volume (by cm3 or cc), number, and distribution prior to TACE or MWA.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2025
- Study start1 Oct 2025 (estimated)
- Primary completion1 Oct 2027 (estimated)
- Study completion1 Nov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatocellular Carcinoma (HCC)Studies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 66 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Saber Hamed Ahmed, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07183566
- Sponsor's protocol ID
- Ct volume measaurement of HCC
- Status last verified
- Sep 2025
- First submitted
- 12 Sep 2025
- Last updated
- 19 Sep 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 19 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ct Volume Measurement of Hepatocellular Carcinoma After Transarterial Chemoembolization (TACE) or Microwave Ablation (MWA)
- ClinicalTrials.gov ID
- NCT07183566
- Acronym / sponsor ID
- Ct volume measaurement of HCC
- Conditions
- Hepatocellular Carcinoma (HCC), CT
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 66 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Oct 2025 (estimated)
- Primary completion
- 1 Oct 2027 (estimated)
- Study completion
- 1 Nov 2027 (estimated)
- First posted
- 19 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to evaluate the role of CT volumetric measurement in assessing treatment response of hepatocellular carcinoma (HCC) following trans arterial chemoembolization (TACE) or microwave ablation (MWA)
Detailed description
Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer and a major contributor to cancer-related mortality worldwide (1). Conventional curative interventions for HCC encompass liver transplantation, hepatic resection, and thermal ablation. Regrettably, fewer than 30% of patients qualify for surgery upon diagnosis, and many tumor-related characteristics, including size and location, may inhibit the application of thermal ablative methods .
In these cases, locoregional therapies such as transarterial chemoembolization (TACE) and microwave ablation (MWA) play a pivotal role. Both techniques aim to achieve local tumor control and improve patient survival. TACE induces ischemic necrosis through targeted delivery of chemotherapeutic agents combined with arterial embolization, whereas MWA achieves tumor destruction by generating high-frequency electromagnetic waves that produce thermal coagulative necrosis. Accurate assessment of treatment response is essential for guiding clinical decisions and predicting outcomes. Conventional imaging-based response criteria, such as RECIST and mRECIST, primarily focus on changes in lesion diameter. However, these methods may not fully reflect the extent of tumor necrosis or viable residual tissue . In this context, CT-based volumetric measurements have emerged as a more objective and sensitive tool for evaluating therapeutic response after locoregional treatment. Volumetric analysis provides a three-dimensional assessment of tumor burden and may bet ter correlate with treatment efficacy and prognosis compared to traditional linear measurements. Therefore, this study aims to investigate the role of CT volumetric measurement of HCC after TACE or microwave ablation in evaluating treatment response and predicting clinical outcomes .
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- All patients admitted to Assiut University Hospital, Egypt during the period of the study and fulfil the inclusion criteria
Key inclusion criteria (5 listed)
- Adult patients (≥18 years) with a confirmed diagnosis of HCC based on AASLD or EASL criteria.
- Patients deemed unresectable by the multidisciplinary tumor board.
- Patients scheduled for TACE as the primary locoregional therapy.
- Preserved liver function (Child-Pugh class A or B).
- Adequate renal function to permit contrast-enhanced CT.
Key exclusion criteria (4 listed)
- Patients with extrahepatic metastases or portal vein thrombosis.
- Patients with contraindications to iodinated contrast or TACE.
- Patients with severe comorbid illness that precludes participation.
- Patients refuse to provide informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CtCt volume measurement of HCC after TACE or MWA | Device | – |
Primary outcome
Ct volume measurent of hepatocellular carcinoma after Transarterial chemoembolization or microwave ablation
Time frame: Baseline
At enrollment, all patients will undergo a comprehensive clinical assessment, including full medical history with emphasis on risk factors for hepatocellular carcinoma triphasic CT scan of the liver, which will serve as the reference for tumor volume (by cm3 or cc), number, and distribution prior to TACE or MWA.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Sep 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Hepatocellular Carcinoma (HCC)
RecruitingObservational study
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Liver Neoplasms, Primary Liver Cancer
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingObservational study
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Lung Cancer, Hepatocellular Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Hepatocellular Carcinoma (HCC) and CT, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ahmes Saber Hamed, Master (+2001019545804, Ahmed.17289721@med.aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Ct volume measurent of hepatocellular carcinoma after Transarterial chemoembolization or microwave ablation (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2025.